- Details
- Description
LuciLorla (Lorlatinib) is a targeted anticancer medicine containing lorlatinib, a selective inhibitor of ALK (anaplastic lymphoma kinase) and ROS1 tyrosine kinases. Lorlatinib is designed to block abnormal signaling pathways that can contribute to the growth and spread of cancer cells.
Lorlatinib is used for the treatment of certain patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). It may be used when the tumor contains an ALK alteration identified through appropriate molecular testing and according to approved treatment indications.
LuciLorla is an oral medicine intended for use under the supervision of a qualified healthcare professional. The appropriate dosage, treatment duration, monitoring, and management of potential adverse reactions or drug interactions should be determined by the treating physician.
Product strength, packaging, manufacturer, availability, and regulatory status may vary depending on the market and specific product presentation. Healthcare professionals should consult the applicable official prescribing information before prescribing or dispensing this medicine.
